

**Table F-3. Key findings in studies of nutritional interventions**

<p><b>Author, Year Study Design</b></p> <p><b>Groups (dose), N enrollment / N final</b></p> <p><b>Treatment duration/Follow-up timepoint post-treatment</b></p> <p><b>Risk of Bias</b></p>	<p><b>Mean age, years ± SD</b></p> <p><b>Mean IQ ±SD</b></p>	<p><b>Outcome measure/Baseline scores, mean ±SD</b></p>	<p><b>Outcome measure/Post- treatment scores, mean ± SD</b></p>
<p>Sun et al., 2016<sup>38</sup> RCT</p> <p>G1: TEACCH+folic acid, 44/44 G2: TEACCH alone, 22/22</p> <p>3 months/EOT</p> <p>Moderate ROB</p> <p>(Note: Discussed in section on combined treatments in main report)</p>	<p>Age (months) G1: 57.23 ± 15.06 G2: 51.75 ± 12.72</p> <p>IQ NR</p>	<p>ABC - Total Score G1: 54.55 ± 26.58 G2: 67.59 ± 27.6</p> <p>CARS – Total Score G1: 33.86 ± 7.08 G2: 33.41 ± 6.04</p> <p>ATEC – Total Score G1: 48.68 ± 21.43 G2: 57.36 ± 20.38</p> <p>PEP – Cognitive Verbal/Preverbal G1: 12 ± 3 G2: 12.95 ± 2.38</p> <p>PEP – Expressive Language G1: 11.41 ± 3.41 G2: 11.91 ± 2.86</p> <p>PEP – Receptive Language G1: 12.36 ± 2.42 G2: 13.32 ± 1.96</p> <p>PEP – Fine Motor G1: 11.8 ± 1.79 G2: 11.91 ± 2</p> <p>PEP – Gross Motor G1: 12.07 ± 1.78 G2: 12.36 ± 1.92</p> <p>PEP – Visual Motor Imitation G1: 11.55 ± 2.17 G2: 12 ± 2.16</p> <p>PEP – Affective Expression G1: 11.8 ± 2.06 G2: 10.95 ± 2.3</p> <p>PEP – Social Reciprocity G1: 10.36 ± 2.08 G2: 10.5 ± 1.87</p>	<p>ABC - Total Score G1: 39.4 ± 26.73 G2: 46.18 ± 22.71 G1 vs G2, p=ns</p> <p>CARS – Total Score G1: 29.34 ± 5.52 G2: 30.82 ± 5.06 G1 vs G2, p=ns</p> <p>ATEC – Total Score G1: 36.3 ± 17.49 G2: 46.36 ± 18.56 G1 vs G2, p=0.052</p> <p>PEP – Cognitive Verbal/Preverbal G1: 14.2 ± 1.97 G2: 13.91 ± 2.79 G1 vs G2, p=ns</p> <p>PEP – Expressive Language G1: 13.07 ± 3.19 G2: 13.14 ± 2.87 G1 vs G2, p=ns</p> <p>PEP – Receptive Language G1: 13.75 ± 1.4 G2: 13.73 ± 1.75 G1 vs G2, p=ns</p> <p>PEP – Fine Motor G1: 12.48 ± 1.68 G2: 13 ± 1.75 G1 vs G2, p=ns</p> <p>PEP – Gross Motor G1: 12.77 ± 0.99 G2: 13.09 ± 1.31 G1 vs G2, p=ns</p> <p>PEP – Visual Motor Imitation G1: 12.27 ± 1.48 G2: 13.64 ± 1.97 G1 vs G2, p=ns</p> <p>PEP – Affective</p>

<p><b>Author, Year Study Design</b></p> <p><b>Groups (dose), N enrollment / N final</b></p> <p><b>Treatment duration/Follow-up timepoint post-treatment</b></p> <p><b>Risk of Bias</b></p>	<p><b>Mean age, years ± SD</b></p> <p><b>Mean IQ ±SD</b></p>	<p><b>Outcome measure/Baseline scores, mean ±SD</b></p>	<p><b>Outcome measure/Post- treatment scores, mean ± SD</b></p>
		<p>PEP – Characteristic Motor Behaviors G1: 11.98 ± 2.39 G2: 11.95 ± 2.3</p> <p>PEP – Characteristic Verbal Behaviors G1: 8 ± 3.58 G2: 9.05 ± 2.9</p> <p>PEP – Communication G1: 35.77 ± 8.21 G2: 38.18 ± 6.71</p> <p>PEP – Motor G1: 35.41 ± 5.18 G2: 36.27 ± 5.54</p> <p>PEP – Maladaptive Behavior G1: 42.14 ± 7.84 G2: 42.45 ± 7.31</p> <p>PEP – Problem Behaviors G1: 8.25 ± 2.36 G2: 8.27 ± 2.39</p> <p>PEP – Personal Self-Care G1: 11.7 ± 2.41 G2: 12.09 ± 2.24</p> <p>PEP – Adaptive Behaviors G1: 11.14 ± 2.36 G2: 11.36 ± 2.63</p>	<p>Expression G1: 11.98 ± 2.25 G2: 12.45 ± 1.26 G1 vs G2, p=ns</p> <p>PEP – Social Reciprocity G1: 11.3 ± 2.09 G2: 11.64 ± 1.65 G1 vs G2, p=ns</p> <p>PEP – Characteristic Motor Behaviors G1: 11.66 ± 2.58 G2: 12.59 ± 2.26 G1 vs G2, p=ns</p> <p>PEP – Characteristic Verbal Behaviors G1: 9.64 ± 3.72 G2: 10.5 ± 2.65 G1 vs G2, p=ns</p> <p>PEP – Communication G1: 41.02 ± 5.91 G2: 40.77 ± 7.04 G1 vs G2, p=ns</p> <p>PEP – Motor G1: 37.52 ± 3.79 G2: 38.73 ± 4.69 G1 vs G2, p=ns</p> <p>PEP – Maladaptive Behavior G1: 44.57 ± 9.59 G2: 47.18 ± 6.53 G1 vs G2, p=ns</p> <p>PEP – Problem Behaviors G1: 9.05 ± 2.9 G2: 9 ± 2.65 G1 vs G2, p=ns</p> <p>PEP – Personal Self-Care G1: 12.34 ± 1.7 G2: 12.41 ± 2.48 G1 vs G2, p=ns</p>

<p><b>Author, Year Study Design</b></p> <p><b>Groups (dose), N enrollment / N final</b></p> <p><b>Treatment duration/Follow-up timepoint post-treatment</b></p> <p><b>Risk of Bias</b></p>	<p><b>Mean age, years ± SD</b></p> <p><b>Mean IQ ±SD</b></p>	<p><b>Outcome measure/Baseline scores, mean ±SD</b></p>	<p><b>Outcome measure/Post- treatment scores, mean ± SD</b></p>
			<p>PEP – Adaptive Behaviors G1: 12.32 ± 2.59 G2: 11.77 ± 2.51 G1 vs G2, p=ns</p>
<p>Mankad et al., 2015<sup>39</sup> RCT</p> <p>G1: Omega-3 fatty acid (3.5 mL/day), 19/18 G2: Placebo, 19/19</p> <p>6 months/EOT</p> <p>Moderate RoB</p>	<p>Age G1: 3.5 ± 1.1 G2: 3.8 ± 1.0</p> <p>IQ NR</p>	<p>Baseline scores NR</p>	<p><b>Change from Baseline</b></p> <p>PDDBI – Autism Composite G1: -4.5 G2: -6.4 G1 vs G2: p=ns</p> <p>BASC – Externalizing G1: 3.2 G2: -3.0 G1 vs G2: p=0.02</p> <p>CGI G1: NR G2: NR G1 vs G2:p=ns</p> <p>VABS G1: 2.8 G2: -0.2 G1 vs G2: p=ns</p> <p>Preschool Language Scale (PLS4) G1: 0.7 G2: -0.6 G1 vs G2: p=ns</p>
<p>Saad et al., 2015<sup>40</sup> RCT</p> <p>G1: Digestive enzymes (15 mL/day), 51/47 G2: Placebo (NA), 50/45</p> <p>3 months/EOT</p> <p>Moderate RoB</p>	<p>Age G1: 5.94 ± 2.01 G2: 5.87 ± 2.12</p> <p>IQ NR</p>	<p>CARS G1: 36.1 ± 3.7 G2: 35.3 ± 4.0</p> <p>GBRS Child's General Behavior G1: 3.01 ± 1.3 G2: 3.50 ± 0.7</p> <p>Nighttime sleeping G1: 3.89 ± 1.3 G2: 3.84 ± 1.0</p>	<p><b>EOT</b></p> <p>CARS G1: 31.2 ± 1.2 G2: 35.5 ± 2.8 G1 vs G2: p=0.034</p> <p>GBRS Child's General Behavior G1: 5.5 ± 0.75 G2: 3.39 ± 1.01 G1 vs G2:, p&lt;0.001</p> <p>Nighttime sleeping</p>

<p><b>Author, Year Study Design</b></p> <p><b>Groups (dose), N enrollment / N final</b></p> <p><b>Treatment duration/Follow-up timepoint post-treatment</b></p> <p><b>Risk of Bias</b></p>	<p><b>Mean age, years ± SD</b></p> <p><b>Mean IQ ±SD</b></p>	<p><b>Outcome measure/Baseline scores, mean ±SD</b></p>	<p><b>Outcome measure/Post- treatment scores, mean ± SD</b></p>
		<p>Gastrointestinal symptoms G1: 3.79 ± 0.61 G2: 4.02 ± 0.28</p> <p>Daytime wetting G1: 3.86 ± 0.67 G2: 3.92 ± 0.83</p> <p>Nighttime wetting G1: 4.60 ± 0.97 G2: 3.92 ± 0.6</p>	<p>G1: 4.02 ± 1.20 G2: 3.98 ± 0.89 G1 vs G2: p=ns</p> <p>Gastrointestinal symptoms G1: 6.03 ± 0.56 G2: 4.02 ± 0.23 G1 vs G2: p&lt;0.001</p> <p>Daytime wetting G1: 3.97 ± 0.88 G2: 4.03 ± 1.04 G1 vs G2: p=ns</p> <p>Nighttime wetting G1: 4.23 ± 1.25 G2: 4.09 ± 0.64 G1 vs G2: p=ns</p>
<p>Bent et al., 2014<sup>41</sup> RCT</p> <p>G1: Omega-3 fatty acid (1.3g/day), 29/29 G2: Placebo, 28/28</p> <p>6 weeks/EOT</p> <p>Moderate RoB</p>	<p>Age, months G1: 88.2 ± 12.3 G2: 85 ± 13.2 mos</p> <p>IQ NR</p>	<p>ABC- Hyperactivity Parent Ratings G1: 28.4 ± 8.4 G2: 28.1 ± 7.6</p> <p>ABC-Hyperactivity Teacher Ratings G1: 18.1 ± 12.0 G2: 14.6 ± 4</p> <p>ABC-Irritability Parent G1: 20.0 ± 8.9 G2: 16.8 ± 8.3</p> <p>ABC-Irritability Teacher G1: 14.3 ± 9.8 G2: 9.4 ± 9.3</p> <p>ABC-Stereotypy Parent G1: 8.0 ± 6.0 G2: 5.4 ± 4.7</p> <p>ABC-Stereotypy Teacher G1: 5.1 ± 4.8 G2: 3.7 ± 4.1</p> <p>ABC-Lethargy Parent G1: 12.2 ± 8.8 G2: 8.8 ± 4.2</p>	<p><b>Mean change score</b> ABC – Hyperactivity Parent G1: -5.3 ± 7.2 G2: -3.4 ± 7.5 G1 vs G2: p=ns</p> <p>ABC- Hyperactivity Teacher G1: -2.6 ± 8.0 G2: -1.0 ± 10.0 G1 vs G2: p=ns</p> <p>ABC-Irritability Parent G1: -2.0 ± 6.9 G2: -2.1 ± 4.4 G1 vs G2: p=ns</p> <p>ABC-Irritability Teacher G1: -1.3 ± 8.6 G2: -0.2 ± 6.8 G1 vs G2: p=ns</p> <p>ABC-Stereotypy Parent G1: -2.0 ± 3.7 G2: -0.5 ± 2.6 G1 vs G2: p=0.05</p> <p>ABC-Stereotypy Teacher</p>

<p><b>Author, Year Study Design</b></p> <p><b>Groups (dose), N enrollment / N final</b></p> <p><b>Treatment duration/Follow-up timepoint post-treatment</b></p> <p><b>Risk of Bias</b></p>	<p><b>Mean age, years ± SD</b></p> <p><b>Mean IQ ±SD</b></p>	<p><b>Outcome measure/Baseline scores, mean ±SD</b></p>	<p><b>Outcome measure/Post- treatment scores, mean ± SD</b></p>
		<p>ABC-Lethargy Teacher G1: 9.9 ± 8.9 G2: 8.3 ± 7.1</p> <p>ABC-Inappropriate speech Parent G1: 7.0 ± 3.4 G2: 5.8 ± 2.8</p> <p>ABC-Inappropriate speech Teacher G1: 4.2 ± 3.9 G2: 3.1 ± 3.3</p> <p>SRS-total G1: 89.7 ± 12.7 G2: 88.3 ± 7</p> <p>CGI-S G1: 3.8 ± 1.0 G2: 4.0 ± 0.79</p>	<p>G1: -1.0 ± 4.2 G2: -0.7 ± 3.2 G1 vs G2: p=ns</p> <p>ABC-Lethargy Parent G1: -2.1 ± 4.2 G2: 0.1 ± 2.6 G1 vs G2: p=0.01</p> <p>ABC-Lethargy Teacher G1: -2.5 ± 7.9 G2: -1.6 ± 5.5 G1 vs G2: p=ns</p> <p>ABC-Inappropriate speech Parent G1: -0.6 ± 2.7 G2: -0.9 ± 2.2 G1 vs G2: p=ns</p> <p>ABC-Inappropriate speech Teacher G1: -1.0 ± 2.6 G2: -0.1 ± 5.5 G1 vs G2: p=ns</p> <p>SRS-total G1: -2.6 ± 8.3 G2: -6.1 ± 7.8 G1 vs G2:p=ns</p> <p>CGI-S G1: NR G2: NR</p>
<p>Voigt et al., 2014<sup>42</sup> RCT</p> <p>G1: Docosahexaenoic acid (DHA) (500 mg/day), 24/19 G2: Placebo, 24/15</p> <p>6 months/EOT</p> <p>Moderate RoB</p>	<p>Age G1: 5.8 ± 1.8 G2: 6.5 ± 2.2</p> <p>IQ NR</p>	<p>CGI-I Parent NR</p> <p>BASC – Parent G1: 26.5 ± 7.1 G2: 30.3 ± 9.1</p> <p>BASC – Teacher G1: 32.2 ± 7.6 G2: 38.5 ± 4.3</p>	<p>CGI-I Parent <b>3 months</b> G1: 4/21 (19) G2: 5/16 (31) G1 vs G2: p=ns</p> <p><b>6 months</b> G1: 5/18 (28) G2: 2/13 (15) G1 vs G2: p=ns</p> <p>CGI-I Investigator <b>3 months</b> G1: 1/17 (6)) G2: 0/13 (0) G1 vs G2: p=ns</p>

<p><b>Author, Year Study Design</b></p> <p><b>Groups (dose), N enrollment / N final</b></p> <p><b>Treatment duration/Follow-up timepoint post-treatment</b></p> <p><b>Risk of Bias</b></p>	<p><b>Mean age, years ± SD</b></p> <p><b>Mean IQ ±SD</b></p>	<p><b>Outcome measure/Baseline scores, mean ±SD</b></p>	<p><b>Outcome measure/Post- treatment scores, mean ± SD</b></p>
			<p><b>6 months</b> G1: 0/18 (0) G2: 1/14 (7) G1 vs G2: p=ns</p> <p><b>EOT</b> BASC – Parent G1: 26.3 ± 6.8 G2: 33.3 ± 9.7 G1 vs G2: p=0.04</p> <p>BASC – Teacher G1: 33.6 ± 9.3 G2: 34.0 ± 5.6 G1 vs G2: p=0.02</p>
<p>Al-Ayadhi et al., 2013<sup>43</sup> RCT</p> <p>G1: Raw camel milk (500 mL/day), 24/24 G2: Boiled camel milk (500 mL/day), 25/25 G3: Cow milk (500 mL/day), 11/11</p> <p>2 weeks/EOT</p> <p>High RoB</p>	<p>Age 2-12</p> <p>IQ NR</p>	<p>CARS – total score G1: 37.63 ± 6.31 G2: 36.82 ± 3.27 G3: 34.18 ± 3.25</p>	<p><b>EOT</b> CARS – total score G1: 34.54 ± 5.19 G2: 33.8 ± 4.91 G3: 34.41 ± 3.25 p=NR</p>
<p>Fahmy et al. 2013<sup>44</sup> RCT</p> <p>G1: Levocarnitine, 16/16 G2: Placebo, 14/14</p> <p>6 months/EOT</p> <p>Moderate RoB</p>	<p>Age (months) G1: 69 (29-103) G2: 68.5 (32- 98)</p> <p>IQ NR</p>	<p>CARS – Mild/Moderate Severity G1: 1 (6.3) G2: 9 (64.3)</p> <p>CARS – Severe G1: 15 (93.80) G2: 5 (35.7)</p> <p>CARS-Total Score G1: 45.25 ± 6.191 G2: 36.71 ± 5.594</p>	<p><b>EOT</b> Mild/Moderate Severity G1: 9 (56.3) G2: 9 (64.3) G1 vs G2, p=ns</p> <p>CARS – Severe G1: 7 (43.8) G2: 5 (35.7) G1 vs G2, p=ns</p> <p>CARS-Total Score G1: 37.06 ± 5.882 G2: 34.71 ± 4.631 G1 vs G2, p&lt;0.001</p>
<p>Bent et al., 2011<sup>45</sup> RCT</p> <p>G1: Omega-3 fatty acid (1.3 g/day), 14/13 G2: Placebo, 13/12</p> <p>12 weeks/EOT</p>	<p>Age, months G1: 70.2 ± 22 G2: 69.8 ± 17</p> <p>IQ G1: 77.5 ± 27 G2: 77.5 ± 17</p>	<p>ABC –Hyperactivity G1: 16.8 ± 13 G2: 20.3 ± 8</p> <p>PPVT G1: 72.2 ± 28 G2: 85.8 ± 12</p> <p>EVT</p>	<p><b>Mean change score</b> ABC – Hyperactivity G1: 2.7 ± 4.8 G2: 0.3 ± 7.2 G1 vs G2: p=ns</p> <p>PPVT G1: 2.7 ± 11.6 G2: 1.9 ± 12.4</p>

<p><b>Author, Year Study Design</b></p> <p><b>Groups (dose), N enrollment / N final</b></p> <p><b>Treatment duration/Follow-up timepoint post-treatment</b></p> <p><b>Risk of Bias</b></p>	<p><b>Mean age, years ± SD</b></p> <p><b>Mean IQ ±SD</b></p>	<p><b>Outcome measure/Baseline scores, mean ±SD</b></p>	<p><b>Outcome measure/Post- treatment scores, mean ± SD</b></p>
<p>Low RoB</p>		<p>G1: 70.8 ± 33 G2: 86.4 ± 14</p> <p>SRS G1: 76.9 ± 11 G2: 79.0 ±</p> <p>BASC-Externalizing G1: 53.8 ± 13 G2: 66.3 ± 25</p> <p>BASC- Internalizing G1: 43.3 ± 10 G2: 50.1 ± 9</p> <p>BASC-Behavioral G1: 60.9 ± 14 G2: 65.4 ± 3</p> <p>BASC- Adaptive skill G1: 29.8 ± 9 G2: 31.9 ± 9</p> <p>BASC-Hyperactivity G1: 61.8 ± 17 G2: 64.6 ± 7</p>	<p>G1 vs G2: p=ns</p> <p>EVT G1: 2.2 ± 7.6 G2: 5.8 ± 5.7 G1 vs G2: p=ns</p> <p>SRS G1: -0.9 ± .5 G2: 1.7 ± 7.2 G1 vs G2: p=ns</p> <p>BASC-Externalizing G1: 0.1 ± 6.7 G2: 6.6 ± 30.4 G1 vs G2: p=ns</p> <p>BASC-Internalizing G1: 0.3 ± 6.6 G2: -2.9 ± 7.6 G1 vs G2: p=ns</p> <p>BASC-Behavioral G1: -1.1 ± 6.1 G2: -2.0 ± 4.9 G1 vs G2: p=ns</p> <p>BASC-Adaptive skill G1: 1.8 ± 6.8 G2: 0.8 ± 7.1 G1 vs G2: p=ns</p> <p>BASC-Hyperactivity G1: 2.1 ± 6.3 G2: 1.2 ± 5.8 G1 vs G2: p=ns</p>
<p>Geier, et al., 2011<sup>46</sup> RCT</p> <p>G1: Levocarnitine (50 mg/kg/day), 19/16 G2: Placebo, 11/11</p> <p>3 months/EOT</p> <p>High RoB</p>	<p>Age: G1: 6.3 ± 2.4 G2: 6.7 ± 1.6</p> <p>IQ NR</p>	<p>CARS G1: 35.7±5.3 G2: 38.2±6.0</p> <p>CGI G1: 2.0 G2: 2.0</p> <p>Hand Muscle Testing G1: 32.7±13.9 G2: 35.3±13.2</p> <p>ATEC Total G1: 55.1±23.3 G2: 62.8±31.7</p>	<p><b>EOT</b> CARS G1: 33.8±5.8 G2: 38.4±6.3 p=.02</p> <p>CGI G1: 1.5±0.63 G2: 2.09±0.7 p= .03</p> <p>Hand Muscle Testing G1: 34.3±16.7 G2: 35.1±7.5 p= ns</p>

<p><b>Author, Year Study Design</b></p> <p><b>Groups (dose), N enrollment / N final</b></p> <p><b>Treatment duration/Follow-up timepoint post-treatment</b></p> <p><b>Risk of Bias</b></p>	<p><b>Mean age, years ± SD</b></p> <p><b>Mean IQ ±SD</b></p>	<p><b>Outcome measure/Baseline scores, mean ±SD</b></p>	<p><b>Outcome measure/Post- treatment scores, mean ± SD</b></p>
		<p>ATEC Speech G1: 9.9±6.3 G2: 10.5±6.4</p> <p>ATEC Sociability G1: 12±7.1 G2: 11.9±7.7</p> <p>ATEC Cognitive G1: 12.7±6.1 G2: 14.4±7.6</p> <p>ATEC Health/Behavior G1: 20.5±8.1 G2: 26±14.8</p>	<p>ATEC Total G1: 40.1±22.8 G2: 56±27.6 p= ns</p> <p>ATEC Speech G1: 7.8±5.9 G2: 10.9±7.2 p= ns</p> <p>ATEC Sociability G1: 8.3±5.9 G2: 10.8±8.4 p=ns</p> <p>ATEC Cognitive G1: 9.2±5.5 G2: 14.9±7.3 p=.009</p> <p>ATEC Health/Behavior G1: 14.8±7.9 G2: 19.5±10.9 p=ns</p>
<p>Bertoglio et al., 2010<sup>17</sup> RCT</p> <p>G1: Methyl B12 (64.5 µg/kg) G2: Placebo Crossover design N=30 total</p> <p>12 weeks/EOT</p> <p>Low RoB</p>	<p>Age G1 + G2: 3-8</p> <p>IQ NR</p>	<p>CGIS NR</p>	<p>No significant group difference in behavior measures</p> <p><b>EOT</b> CGIS Improvement (≥1 point) n (%) G1+G2: 9 (30) 3 received placebo first and 6 received active treatment</p> <p>CBCL improvement (≥5 points): G1+G2: 3 (10)</p> <p>ABC improvement (≥5 points): G1+G2: 5 (16.7)</p>



<p><b>Author, Year Study Design</b></p> <p><b>Groups (dose), N enrollment / N final</b></p> <p><b>Treatment duration/Follow-up timepoint post-treatment</b></p> <p><b>Risk of Bias</b></p>	<p><b>Mean age, years ± SD</b></p> <p><b>Mean IQ ±SD</b></p>	<p><b>Outcome measure/Baseline scores, mean ±SD</b></p>	<p><b>Outcome measure/Post- treatment scores, mean ± SD</b></p>
<p>Munasinghe et al., 2010<sup>48</sup> RCT</p> <p>G1: Digestive enzyme supplement- Peptizyde (up to 2 capsules/day) G2: Placebo (360 mg/day) Crossover design N=43 total</p> <p>3 months/EOT</p> <p>Moderate RoB</p>	<p>Age, months G1 + G2: 5.78 ± 1.77</p> <p>IQ NR</p>	<p>GBRS G1+G2: 4</p> <p>ARS G1+G2: 4</p> <p>LDS NR</p>	<p><b>EOT</b></p> <p>Food variety score G1: 4.42 ± 0.62 G2: 4.06 ± 0.45 p= 0.02</p> <p>Parent Behavior score G1: 4.29 ± 0.79 G2: 4.11 ± 0.73 p = ns</p> <p>GI symptoms score G1: 4.01 ± 0.68 G2: 3.87 ± 0.36 p = ns</p> <p>Sleep Quality score G1: 3.95 ± 0.75 G2: 3.87 ± 0.56 p = ns</p> <p>Therapist engagement score G1: 4.59 ± 0.96 G2: 4.43 ± 0.55 p = ns</p> <p>LDS Vocabulary percentile score G1: 56.95 ± 28.6 G2: 55.59 ± 28.6 p = ns</p> <p>LDS Sentence length percentile score G1: 62.38 ± 26.2 G2: 63.91 ± 24.9 p = ns</p>
<p>Hendren et al., 2016<sup>49</sup> RCT</p> <p>G1: Methyl B-12 (75 µg/kg every 3 days), 28/27 G2: Placebo (75 µg/kg every 3 days), 29/23</p> <p>8 weeks/EOT</p> <p>Moderate ROB</p>	<p>Age (months) G1: 67 ± 16 G2: 58 ± 14</p> <p>IQ-Stanford Binet G1: 64 ± 18 G2: 67 ± 20</p>	<p>CGI-Severity G1: 5.2 ± 0.7 G2: 5.1 ± 0.6</p> <p>ABC-Hyperactivity G1: 25 ± 10.1 G2: 22.4 ± 11.5</p> <p>ABC-Inappropriate Speech G1: 4.2 ± 3.2 G2: 2.9 ± 3.2</p>	<p><b>Change Score</b></p> <p>CGI-Improvement G1: 2.4 ± 0.8 G2: 3.1 ± 0.8 G1 vs G2, p=0.005</p> <p>ABC-Hyperactivity G1: -0.9 ± 4.8 G2: -3.9 ± 7.1 G1 vs G2, p=ns; ES=- 0.48</p> <p>ABC-Inappropriate</p>

<b>Author, Year Study Design</b>  <b>Groups (dose), N enrollment / N final</b>  <b>Treatment duration/Follow-up timepoint post-treatment</b>  <b>Risk of Bias</b>	<b>Mean age, years ± SD</b>  <b>Mean IQ ±SD</b>	<b>Outcome measure/Baseline scores, mean ±SD</b>	<b>Outcome measure/Post- treatment scores, mean ± SD</b>
		ABC-Irritability G1: 15.2 ± 10.4 G2: 11.1 ± 8.4  ABC-Social Withdrawal/Lethargy G1: 15 ± 9.1 G2: 14.2 ± 8.5  ABC-Stereotypic Behavior G1: 7.1 ± 4.6 G2: 7.4 ± 5.1  SRS-Total Score G1: 90 ± 13.7 G2: 83.5 ± 10.6	Speech G1: 0.3 ± 1.4 G2: -0.3 ± 1.6 G1 vs G2, p=ns; ES=- 0.43  ABC-Irritability G1: -0.1 ± 3.7 G2: -2.6 ± 4.3 G1 vs G2, p= 0.08; ES=-0.61  ABC-Social Withdrawal/Lethargy G1: -1.9 ± 5.8 G2: -1.2 ± 7.1 G1 vs G2, p=ns; ES=0.12  ABC-Stereotypic Behavior G1: -0.3 ± 2.2 G2: 0.3 ± 3.2 G1 vs G2, p=ns; ES=0.23  SRS-Total Score G1: -1.6 ± 7.7 G2: -4.1 ± 7.7 G1 vs G2, p=ns; ES=- 0.32

ABC-Aberrant Behavior Checklist; CGI-Clinical Global Impression; VABS-Vineland Adaptive Behavior Scale; EOT-End of Treatment; PDDBI-Pervasive Developmental Disorders Behavior Inventory; BASC-Behavior Assessment System for Children; CARS-Childhood Autism Rating Scale; GBRS-Global Rating Scale; SRS-Social Responsiveness Scale; PPVT-Peabody Picture Vocabulary Test; EVT-Expressive Vocabulary Test; ATEC-Autism Treatment Evaluation Checklist; CGIS-Clinical Global Impressions Scale; CBCL-Child Behavior Checklist; GBRS-Global Rating Scale; ARS-Additional Rating Scale; LDS-Language Development Survey